Spain · Delayed Price · Currency is EUR Almirall Earnings Call Transcripts
Fiscal Year 2025
-
Delivered strong 2025 results with 12.4% net sales growth and 21% EBITDA increase, driven by European dermatology and biologics. 2026 guidance targets 9%-12% sales growth and continued margin expansion, supported by a robust pipeline and financial flexibility.
-
Strong double-digit sales and EBITDA growth in the first nine months of 2025 were driven by Illumetri and Ebgly, with robust European dermatology performance and a solid pipeline. Guidance for 2025 and midterm outlook are reiterated, supported by low leverage and ongoing market expansion.
-
Strong H1 2025 results with 13% net sales growth, led by ILUMETRI and Eblis, support reaffirmed guidance and midterm outlook. Robust pipeline progress, disciplined capital allocation, and low leverage position the company for continued growth.
-
Dermatology-focused growth is driven by strong launches of Ebglyss and Ilumetri, with double-digit sales growth and margin expansion expected through 2028. A robust pipeline, stable mature portfolio, and minimal US exposure position the company for sustained value creation.
-
Q1 2025 saw double-digit sales and EBITDA growth, led by Ilumetri and Eblas, with strong European dermatology performance and robust R&D investment. Guidance for 2025 and midterm outlook were reiterated, with minimal tariff risk and continued focus on innovation and market expansion.
-
Strong growth in medical dermatology is driven by leading biologics Ebglyss and Ilumetri, with robust sales, expanding indications, and a promising pipeline. Double-digit sales growth and margin expansion are expected through 2028, supported by disciplined R&D and selective M&A.
Fiscal Year 2024
-
Delivered double-digit net sales and EBITDA growth in 2024, driven by strong performance in European dermatology, especially from Ilumetri and Ebglyss. 2025 guidance targets further sales acceleration and margin expansion, with continued investment in R&D and new launches.
-
Net sales rose 7.9% to EUR 728 million and EBITDA grew 3% in the first nine months of 2024, driven by strong European dermatology performance and successful launches of Ilumetri and EBGLYSS. Guidance for full-year growth is reiterated, with continued investment in R&D and new markets.
-
Strong H1 2024 results with 7% net sales growth and 3.2% EBITDA increase, led by European dermatology. Key products Ilumetri and Ebglyss drove performance, with further launches and R&D progress supporting reiterated full-year guidance.